Fabio Placidi

Oct 23, 2024 | onlinelibrary.wiley.com | Andrea Pilotto |Alice Galli |Cinzia Zatti |Fabio Placidi

Introduction Identifying in vivo markers that reflect risk for phenoconversion to clinically evident alpha-synucleinopathies remains an unmet need. Alpha-synucleinopathies include a spectrum of neurodegenerative disorders characterized by neuronal loss caused by the aggregation of misfolded α-synuclein protein leading to dopaminergic deficits.